NANO Nanobiotix SA

Nanobiotix: Voting Rights and Shares Capital of the Company

PARIS--(BUSINESS WIRE)--

Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq

Euronext Compartment: B

ISIN code: FR0011341205

Nasdaq: NBTX

Bloomberg: NANO:FP

Reuters: NANO.PA

Website:

Date

Number of Shares

Outstanding

 

Total number of voting rights

Total voting rights,

theoretical (1)

 

Total voting rights,

exercisable (2)

September 30, 2022

34,875,872

36,277,898

36,261,825

(1) The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

***

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at or follow us on and .

EN
10/10/2022

Underlying

NANONanobiotix SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Information mensuelle relative au nombre total de droits de vote et d’...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 17 déc. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actionscomposant le capitalsocialNombre total de droits de voteTotal théorique1Total exerçable230 novembre 202548 401 11850 101 69950 079 581 À propos...

December 17, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable2November 30, 202548,401,11850,101,69950,079,581 About NANOBIOTI...

December 17, 2025 1 EN
Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Jean-François Granjon
  • Louis Boujard
  • CFA
ISP INTESA SANPAOLO S.P.A.
NANO NANOBIOTIX SA
ADVI ADVINI
UCG UNICREDIT S.P.A.
FLU FLUGHAFEN WIEN AG
AXS ACCSYS TECHNOLOGIES
ALHAF HAFFNER ENERGY SA
ORP ORPEA
12/16/25 December 16, 2025 1 EN
Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Jean-François Granjon
  • Louis Boujard
  • CFA
ISP INTESA SANPAOLO S.P.A.
NANO NANOBIOTIX SA
ADVI ADVINI
UCG UNICREDIT S.P.A.
FLU FLUGHAFEN WIEN AG
AXS ACCSYS TECHNOLOGIES
ALHAF HAFFNER ENERGY SA
ORP ORPEA
12/16/25 December 16, 2025 1 FR
Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
NANO NANOBIOTIX SA

Nanobiotix : The latest clinical data underpin the investment case

The recent data (phase 1) in melanoma, pancreatic cancer and head and neck cancer with anti-PD1 (first or second line) reinforce, in our opinion, the local action as well as the systemic action of JNJ-1900/NBTXR3. These results confirm what has already been observed in previous clinical studies and support the hypothesis that the candidate drug could become a "backbone therapy" in oncology. The risk-reward profile looks particularly attractive at these valuation levels. We reiterate our Outperfo...

12/16/25 December 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch